Gabapentin and pregabalin are the 2 clinically used medications in the gabapentinoid drug class. Pregabalin and gabapentin have both been approved by the US Food and Drug Administration for treatment of partial seizures and postherpetic neuralgia. Gabapentin enacarbil has also been approved for restless legs syndrome, while pregabalin has additional approvals for diabetic peripheral neuropathy, neuropathic pain associated with spinal cord injury, and fibromyalgia. Gabapentin, in particular, is frequently used for off-label indications.1 There has been controversy around the use of these drugs due to off-label marketing,1 the short-term follow-up of studies,2 potential for addiction,3 possible increased risk of overdose among individuals concomitantly taking opiates,4 and ineffectiveness for common indications.2,5 Given the safety concerns and the implications of widespread use, I set out to characterize the use of gabapentinoids among the adult population.
Johansen ME. Gabapentinoid Use in the United States 2002 Through 2015. JAMA Intern Med. 2018;178(2):292–294. doi:10.1001/jamainternmed.2017.7856
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: